GlassScriptPhysician profile
Peter A Hurtubise
NPI 1558306670
$1,572.23
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $287 · 2021: $698 · 2022: $299 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.01 | 2020-2022 | |
| Pfizer INC. | $364.44 | 2020-2022 | |
| Glaxosmithkline, LLC. | $241.30 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $93.21 | 2021-2022 | |
| Abbvie INC. | $91.86 | 2019 | |
| Amgen INC. | $76.71 | 2020 | |
| Indivior INC. | $71.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.10 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.05 | 2022 | |
| Biodelivery Sciences International, INC. | $26.39 | 2021 | |
| Lumenis, INC | $20.97 | 2021 | |
| Novo Nordisk INC | $20.52 | 2022 | |
| Lilly USA, LLC | $16.09 | 2022 | |
| Eisai INC. | $15.53 | 2021 | |
| Clarus Therapeutics INC. | $14.96 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hurtubise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.